Home Cart Sign in  
Chemical Structure| 1589527-65-0 Chemical Structure| 1589527-65-0

Structure of KIRA6
CAS No.: 1589527-65-0

Chemical Structure| 1589527-65-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

In INS-1 cells, KIRA6 inhibits IRE1α auto-phosphorylation by Tg and XBP1 mRNA splicing by Tm in a dose-dependent manner.

Synonyms: IRE1 Inhibitor IV; IRE1α Kinase Inhibiting RNase Attenuator 6

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of KIRA6

CAS No. :1589527-65-0
Formula : C28H25F3N6O
M.W : 518.53
SMILES Code : O=C(NC1=CC=CC(C(F)(F)F)=C1)NC2=C3C=CC=CC3=C(C4=C5C(N)=NC=CN5C(C(C)(C)C)=N4)C=C2
Synonyms :
IRE1 Inhibitor IV; IRE1α Kinase Inhibiting RNase Attenuator 6
MDL No. :MFCD29477497
InChI Key :NOHQEAFAESMMDX-UHFFFAOYSA-N
Pubchem ID :73425700

Safety of KIRA6

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Description
KIRA6 is highlighted as a sophisticated small-molecule inhibitor targeting the IRE1α RNase kinase, displaying an IC50 of 0.6 µM[2].

In Vitro:

Cell Line
Concentration Treated Time Description References
HEY cells 2 μM 72 hours Kira6 reversed the apoptosis and activation of IRE1α/JNK pathway induced by ROR2 overexpression PMC6933631
HO-8910 cells 2 μM 72 hours Kira6 reversed the apoptosis and activation of IRE1α/JNK pathway induced by ROR2 overexpression PMC6933631
MEL526 cells 100 nM - 1 µM 1 h KIRA6 inhibited KIT phosphorylation at concentrations similar to that of GSK414. PMC6443726
HMC-1.1 cells 10 nM - 1 µM 72 h KIRA6 compromised the viability of KIT-dependent HMC-1.1 cells. PMC6443726
3T3-L1 preadipocytes 1 µM 24 hours To evaluate the inhibitory effect of KT-NE on adipocyte differentiation and lipid droplet accumulation, results showed that KT-NE significantly inhibited adipocyte differentiation and lipid droplet accumulation PMC10761889
HUVECs 1 µM 24 hours To assess the toxicity of KT-NE on normal somatic cells, results showed that KT-NE had negligible toxicity on HUVEC cells within 24 hours PMC10761889
Primary human airway epithelial (HAE) cells 100 nM 72 hours KIRA6 inhibits IL-1β-induced XBP1 splicing and MUC5AC and MUC5B mRNA expression PMC6635783

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Kunming mice Intracerebral hemorrhage model Intranasal administration 5 mg/kg, 10 mg/kg, 20 mg/kg Single administration KIRA6 dose-dependently inhibited p-IRE1α/IRE1α protein expression, increased hematoma volume and neurological deficits. PMC11017440
C57BL/6 mice Traumatic brain injury (TBI) model Intraperitoneal injection 10 mg/kg Once daily for three consecutive days Kira6 alleviated neuroinflammation and neuronal death caused by PAD4 overexpression by inhibiting the IRE1α/ASK1/JNK signaling pathway. PMC10543875
C57BL/6 mice High-fat diet-induced obesity model Subcutaneous injection 4 mg/kg Twice per week for 3 weeks To evaluate the anti-obesity effect of KT-NE in vivo, results showed that KT-NE significantly reduced body weight and fat content in mice and improved hepatic steatosis PMC10761889

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.93mL

0.39mL

0.19mL

9.64mL

1.93mL

0.96mL

19.29mL

3.86mL

1.93mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories